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Abstract
The rapid growth of cancer cells fueled by glycolysis produces large amounts of protons in cancer cells, which tri
mechanisms to transport them out, hence leading to increased acidity in their extracellular environments. It has been well
established that the increased acidity will induce cell death of normal cells but not cancer cells. The main question we
address here is: how cancer cells deal with the increased acidity to avoid the activation of apoptosis. We have carried out a
comparative analysis of transcriptomic data of six solid cancer types, breast, colon, liver, two lung (adenocarcinoma,
squamous cell carcinoma) and prostate cancers, and proposed a model of how cancer cells utilize a few mechanisms to
keep the protons outside of the cells. The model consists of a number of previously, well or partially, studied mechanisms
for transporting out the excess protons, such as through the monocarboxylate transporters, V-ATPases, NHEs and the one
facilitated by carbonic anhydrases. In addition we propose a new mechanism that neutralizes protons through the
conversion of glutamate to c-aminobutyrate, which consumes one proton per reaction. We hypothesize that these
processes are regulated by cancer related conditions such as hypoxia and growth factors and by the pH levels, making these
encoded processes not available to normal cells under acidic conditions.
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Introduction
One of the key cancer hallmarks is their reprogrammed energy
metabolism [1]. That is, glycolysis replaces oxidative phosphory-
lation to become the main ATP producer. A direct result of this
change is that substantially more lactates, as the terminal receivers
of electrons from the glucose metabolism, are produced and
transported out of the cells. To maintain the cellular electro-
neutrality when releasing lactates, the cells release one proton for
each released lactate, the anionic form of lactic acid. This leads to
increased acidity in the extracellular environment of the cancer
cells. It has been well established that high (extracellular) acidity
can induce the apoptotic process in normal cells [2], leading to
their death. Interestingly this does not seem to happen to cancer
cells, hence giving them a competitive advantage over the normal
cells and allowing them to encroach the space occupied by the
normal cells. Currently it is not well understood of how the cancer
cells deal with the increased acidity in their extracellular
environments to avoid acidosis.
A number of studies have been published focused on issues
related to how cancer cells deal with the increased acidity in both
the extracellular and intracellular environments [3,4,5,6,7,8,9].
The majority of these studies were focused on possible cellular
mechanisms for transporting out or neutralizing intracellular
protons, typically focused on one cancer type. More importantly
these studies did not tie such observed capabilities and proposed
mechanisms of cancer cells in avoiding acidosis with the rapid
growth of cancer as we suspect there is an encoded mechanism
that connects the two.
We have carried out a comparative analysis of genome-scale
transcriptomic data on six types of solid cancers, namely breast,
colon, liver, two lung (adenocarcinoma, squamous cell carcinoma)
and prostate cancers, aiming to gain a systems level understanding
of how the cancer cells keep their intracellular pH level within the
normal range while their extracellular pH level is low. Our
analysis, focused on transporters and enzymes, of the transcrip-
tomic data on these cancer and their matching control tissues
indicate that (i) all the six cancer types utilize the monocarboxylate
transporters as the main mechanism to transport out lactates and
protons simultaneously, triggered by the accumulation of intra-
cellular lactates; (ii) these transporters are probably supplemented
by additional mechanisms through anti-porters such as ATPases to
transport protons out in exchange of certain cations such as Ca2+
or Na+ to reduce the intracellular acidity while maintaining the
cellular electron-neutrality; and (iii) cancer cells may also utilize
another mechanism, i.e., using glutamate decarboxylase to
catalyze the decarboxylation of glutamate to a c-aminobutyric
acid (GABA), consuming one proton for each reaction – a similar
process is used by the bacterial Lactococcus lactis to neutralize acidity
when lactates are produced. Based on these analysis results, we
proposed a model that connects these deacidification processes
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with a number of cancer related genes/cellular conditions, which
are probably intrinsic capabilities of fast-growing cells used under
hypoxic conditions rather than gained capabilities through
molecular mutations.
We believe that our study represents the first systemic study
focused on how cancer cells deal with the acidic environment
through the activation of the encoded acid resistance mechanisms
triggered by cancer associated genes and conditions. These results
have established a foundation for a novel model for how cancer
cells avoid acidosis.
Results
1. Cellular Responses to Increased Acidity
The degradation of each mole of glucose generates 2 lactates, 2
protons and 2 ATPs, detailed as
glucosez2ADPz2Pi?2 lactatez2 Hzz2 ATPz2H2O,
showing the source of the increased acidity when glycolysis serves
as the main ATP producer in cancer cells [10]; in contrast the
complete degradation of glucose through oxidative phosphoryla-
tion is pH neutral. Clearly these extra protons need to be removed
or neutralized since otherwise they will induce apoptosis. The
monocarboxylate transporter (MCT), specifically the SLC16A
family, has been reported to play a key role in maintaining the pH
homeostasis [11] with four isoforms, MCT1 - 4, playing crucial
roles in proton-linked transportation [12,13]. Previous studies have
reported that the MCT1, MCT2 and MCT4 genes are up-
regulated in cancer such as in breast, colon, lung and ovary
cancers [14,15]. It has also been observed that a monocarboxylate
transporter pumps out lactates and protons with a 1:1 stoichiom-
etry to maintain cellular electron-neutrality [16].
Our transcriptomic data analyses of the six cancer types added
to this knowledge that these MCT genes also show up-regulation
in five out of the six cancer types. The only exception is the
prostate cancer, which did not show any increased expression of
the MCT genes. Figure 1 shows the transcription up-regulation of
MCT1 (SLC16A1) and MCT4 (SLC16A3) in five cancer types.
Specifically MCT4 shows up-regulation in four of the six cancer
types, an observation that has not been reported before.
One published study suggests that MCT1 might be regulated by
p53 [17] in cancer. Another study shows strong evidence that
MCT1 and MCT4 are regulated by the intracellular level of
hypoxia. We hypothesize that hypoxia may be the main regulating
Figure 1. Expression-level changes of V-ATPase and related genes in six cancer types in comparison with their matching control
tissues. Each entry in the table shows the ratio between a gene’s expression levels in cancer and the matching control, averaged across all the
samples.
doi:10.1371/journal.pone.0071177.g001
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factor of the over-expression of the MCT genes, which may
require additional conditions such as the pH level or the
accumulation of lactates as the co-regulating factors, as suggested
by our analysis result of transcriptomic data of cell lines collected
under hypoxic condition, where MCT1 and MCT4 genes are up-
regulated (see Figure 1 and Figure S1 for details).
The protons transported out of the cells will increase the acidity
of the extracellular environment. Previous studies have shown that
(normal) cells tend to adjust their intracellular pH level to a similar
pH level of the extracellular environment [18]. It has been well
established that the increased intracellular acidity will induce
apoptosis through directly activating the caspase genes, which
bypasses the more upstream regulatory proteins of the apoptosis
system such as p53, hence leading to death of the normal cells that
do not seem to have the right intracellular conditions to deal with
the reduced pH.
2. Additional Mechanisms for Dealing with Excess
Protons in Cancer Cells
We have examined if other genes may be relevant to the
removal or neutralization of protons in cancer cells in a systematic
manner across all the human genes. Our main findings are
summarized in Figure 1, detailed as follows.
V-ATPase. Transmembrane ATPases import many of the
metabolites necessary for cellular metabolisms and export toxins,
wastes and solutes that can hinder the health of the cells [19]. One
particular type of ATPase is the V-ATPase that transports solutes
out using ATP hydrolysis as the energy. It pumps out a proton in
exchange for an extracellular Na+ or another cation such as K+ or
Ca2+ to maintain the intracellular electro-neutrality. V-ATPases
have been found to be up-regulated in multiple cancer types, but
the previous studies have been mostly focused on using the
increased V-ATPase gene expression levels as a biomarker for
metastasis [20] or on utilizing them as potential drug targets as a
way to trigger apoptosis, hence causing cancer cell death
[20,21,22].
We have examined the expression levels of the 19 genes that
encode the subunits of V-ATPase, the V0 (transmembrane)
domain and the V1 (cytoplasmic) domain, namely ATP6V0A1,
ATP6V0A2, ATP6V0B, ATP6V0E1, ATP6V0E2, ATP6AP1 and
ATP6AP2 for V0 and ATP6V1A, ATP6V1B1, ATP6V1C1,
ATP6V1C2, ATP6V1D, ATP6V1E1, ATP6V1E2, ATP6V1F,
ATP6V1G1, ATP6V1G2, ATP6V1G3 and ATP6V1H for V1.
We found that multiple V-ATPase genes are up-regulated,
indicating that the V-ATPases are active in transporting the
protons out. Interestingly some of the ATPase genes do not show
up-regulation and some even show down-regulation in prostate
cancer (Figure 1). More detailed examination of the gene
expression data indicates that the actual expression levels of the
ATPase genes are at the baseline level in both the prostate cancer
and the adjacent control issues, hence the fold-change data are not
particularly informative. Overall the data on prostate cancer seem
Figure 2. Expression level changes of genes involved in carbonic anhydrases (CAs) pH regulation in six cancer tissues in
comparison with their matching control tissues.
doi:10.1371/journal.pone.0071177.g002
Figure 3. Expression level changes of genes involved in the conversion of glutamate to GABA and CO2, along with the genes
encoding the GABA transporters.
doi:10.1371/journal.pone.0071177.g003
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to suggest that the acidity level in this cancer type is not
substantially elevated. For the other five cancer types, the
expression levels of some V-ATPase genes do not show changes
in cancer. We note that these gene expression levels are also
elevated in the control tissues compared to cell-line data of the
matching tissue types (data not shown here), which is consistent
with previously published data, suggesting that the elevated acidic
level in the extracellular environment can also induce increased
expression of the V-ATPase genes in normal tissues [23]. This may
explain why some of the V-ATPase genes do not show
overexpression in cancer versus adjacent control tissues.
Then the question is why cancer cells seem to handle the
increased acidity better than the normal cells. Our hypothesis is
that while pH may play some regulatory role of the expression of
the V-ATPase genes, the main regulator of the V-ATPase is
probably mTORC1 as it has been recently suggested [24].
mTORC is one of the most important regulators relevant to cell
growth, and it generally has dysregulated expressions in cancer.
To check on this hypothesis, we have examined the gene
expression level of mTORC1 (the GBL and FRAP1 genes) in
the six cancer types. We see clear up-regulation of these genes in
all six cancer types as shown in Figure 1. So overall we speculate
that it is the combined effect of decreased pH and up-regulation of
mTORC1 that makes cancer cells more effective in pumping out
the excess protons than the normal cells.
Na+-H+ Exchanger (NHE). NHE anti-porters represent
another class of proteins that can transport out protons and
exchange for a cation to maintain intracellular electro-neutrality.
We have examined the five genes encoding this class of
transporters, and found that these genes are highly up-regulated
in the two lung cancer types. Interestingly the expression-change
patterns are highly complementary between NHE genes and the
V-ATPase genes in five out of the six cancer types, specifically up-
Figure 4. Regulatory relationships between genes involved in deacidification and cancer growth. Each circle represents a
deacidification-related gene, each hexgon represents an oncogene and each triangle a tumor suppressor gene, with each link representing a direct
regulatory relationship.
doi:10.1371/journal.pone.0071177.g004
Figure 5. A model for deacdification in cancer cells. Each cylinder
represents a pump or transporter used to remove protons and possibly
other molecules out of the cell; and each rectangle bar represents a
condition that is a possible regulatory factor for the corresponding
pump or transporter.
doi:10.1371/journal.pone.0071177.g005
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regulation in breast, colon and liver cancers but not in the two
lung cancer types as shown in Figure 1. Hence we speculate that
the NHE anti-porters may play a complementary role to that of
the V-ATPases through coordinated regulation by an unknown
mechanism. Literature search suggests that NHEs are regulated by
both growth factors and pH among a few other factors [25], which
partially explains why the system is more active in cancer (affected
by both growth factors and pH) than in control tissues (affected by
pH only).
3. Carbonic Anhydrases Play Roles in pH Neutralization in
Cancer Cells
It has been previously suggested that carbonic anhydrases (CAs)
play a role in neutralizing the protons in cancer cells. For example,
a model of how the membrane-associated CAs facilitate out-
transportation of protons has been presented [26]. The key idea of
the model is that the membrane bound CAs catalyze the otherwise
slow reaction from CO2+ H2O to H2CO3, which dissociates into
HCO3





2 (bicarbonate) is then transported across the
membrane through an NBC transporter [27] into the intracellular
environment, where it reacts with a H+ to form a CO2 and H2O;
and the CO2 is freely membrane-permeable to get outside the cell,
forming a cycle for removing some of the excess H+. See Figure S1
for a more detailed picture of this mechanism.
To check if the model is supported by the transcriptomic data
being analyzed in our study, we note that (1) three membrane-
associated CAs (CA9, CA12, CA14) show up-regulation in five out
of six cancer types (except for prostate cancer), as shown Figure 2;
and (2) two of the three NBC genes, NBC2 (SLC4A5) and NBC3
(SLC4A7), show up-regulation in four cancer types. It has been
reported that CA9 and CA12 are hypoxia-inducible in brain
cancer [28]. Hence we hypothesize that all the three above
membrane-associated CAs are inducible by hypoxia. In addition,
our literature search indicates that the NBC genes are pH
inducible [29].
Interestingly all the cytosolic CAs (CA2, CA3, CA7, CA13)
show down-regulation, reflecting that oxidative phosphorylation is
not being used as actively and hence produces less CO2 in cancer
cells as in normal cells.
4. Neutralization of Acidity through Decarboxylation
Reactions: A Novel Mechanism?
Our search for possible mechanisms of cancer cells in
deacidification led us to study how Lactococcus lactis deals with the
lactic acids. We note that the bacteria use the glutamate
decarboxylases (GAD) to consume one (dissociable) H+ during






The reaction converts a glutamate to one c-aminobutyrate
(GABA) plus a CO2. Two human homologues of the GAD, GAD1
and GAD2, have been found. Published studies have shown that
the activation of the GAD genes leads to GABA synthesis in
human brain [31], suggesting that the human GAD genes have the
same function as the bacterial GAB gene, i.e., catalyzing the
reaction for the synthesis of GABA. The majority of these studies
were done in the context of the nervous system in human brains
[32,33,34]. Specifically, GABA is known to serve as a key
inhibitory neurotransmitter. In addition, activities of GABA have
been found in human liver [35]. While hypotheses have been
postulated about its functions in liver [36], no solid evidence has
been established about its function there.
We have observed that GAD1 is up-regulated in three out six
cancer types under study, namely colon, liver and lung adenocar-
cinoma, and GAD2 is up-regulated in prostate cancer. It has been
fairly well established that glutamate, the substrate of the above
reaction catalyzed by GAD, is elevated in cancer in general [37].
Hence it makes sense to assume that the above reaction indeed
takes place in cancer. This is supported by our observation that
multiple in-take transporters of glutamate are up-regulated in five
out six cancer types (see Figure 3). An even more interesting
observation is that multiple genes encoding the out-going
transporters of GABA are up-regulated in five out of the six
cancer types, indicating that the GABA molecules are not being
used by cancer cells but instead serve a way to remove H+ out of
the cells.
Currently, to the best of our knowledge no published data are
available to implicate which genes encode the main regulator of
the GAD genes. Interestingly, our search for possible regulators of
the GAD genes in the Cscan database [38] revealed that FOS, a
known oncogene, can potentially regulate the GAD genes [39].
Some experimental data from the ENCODE database [40] show
that the expression of the GAD1 gene (NM_000817, NM_013445)
is positively co-related with that of FOS in the HUVEC cell-line.
Integrating this information, we hypothesize that FOS, in
conjunction with some pH–associated regulator, regulates the
GAD genes, which leads to the synthesis of GABA and reduces
one H+ as a by-product per synthesized GABA; then the unneeded
GABA molecules are transported out of the cells. This may
provide another mechanism that cancer cells use to keep their
intracellular pH level in the normal range.
5. A Model for Cancer Cells to Keep their Intracellular pH
in the Normal Range
Overall 44 genes are implicated in our above analyses. Our
search results of these genes against Cscan database [38] indicate
that 28 of these genes are regulated directly by nine proto-
Table 1. A summary of the cancer datasets used in our
transcriptomic data analysis.
set1 set2 pairs
breast cancer GSE14999 [44] GSE15852 [45] 61/43
colon cancer GSE18105 [46] GSE25070 [47] 17/26
liver cancer GSE22058 [48] GSE25097 [49] 97/238
lung adenocarcinoma GSE31552 [50] GSE7670 [51] 31/26
lung squamous cell
carcinoma
GSE31446 [52] GSE31552 [50] 13/17
prostate cancer GSE21034 [53] GSE6608 [54] 29/58
doi:10.1371/journal.pone.0071177.t001
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oncogenes, namely BCL3, ETS1, FOS, JUN, MXI1, MYC,
PAX5, SPI1 and TAL1; and 17 genes are regulated by two tumor-
suppressors, IRF1 and BRCA1 as shown in Figure 4, indicating
that there is a strong connection between deacidification and
cancer growth.
Figure 5 summarizes our overall model for the cellular
deacidification mechanisms and the associated conditions that
may trigger each mechanism to be activated. Specifically, we
hypothesize that hypoxia and growth factors may serve as the
main regulatory factors of the deacdification processes, hence
making them available only in cancer cells, in conjunction with the
cellular pH level.
Discussion
Based on comparative transcriptomic data analysis results on six
cancer types, we have proposed a model of how cancer cells deal
with excess protons in both intracellular and extracellular
environments, which are generated due to the reprogrammed
energy metabolism. Some of the mechanisms have been reported
in the literature but mostly in a fewer cancer types. Our analysis
results have confirmed and expanded the models previously
proposed. In addition we have proposed a new model based on
how bacterial Lactococcus deals with a similar situation. Another
contribution of the work is that we have proposed possible
regulatory mechanisms that allow cancer cells to fully utilize these
encoded deacidification mechanisms that are not triggered in
normal cells.
Since our proposed model is based on transcriptomic data only,
further experimental validation on a number of the hypotheses are
clearly needed, including (i) the main regulators of these processes
and their regulatory relationships with pH related regulators, (ii)
the new mechanism proposed based on a homologous system in
Lactococcus, the organism that produces lactate; and (iii) the
proposed NBC cotransporter transports in HCO3
2 and Na+
together, but it is not clear how the Na+ is handled in cancer cells;
and similar questions can be asked about the inported Ca2+ or Na+
by other deacidification processes. All these require further
investigation both experimentally and computationally.
Our overall search procedure for enzymes and transporters that
may change the number of protons in a systematic manner proves
to be highly effective. For example, the carbonic anhydrases are
found to be possibly relevant to the deacidification process from
the search; only later we found that this system has been studied
and reported in the literature. This result clearly shows the power
of this procedure, when coupled with additional searches and
analyses of the transcriptomic data, which we believe to be
applicable to elucidation of other cancer-related processes.
Materials and Methods
1. Gene Expression Data for Six Cancer Types
The gene-expression data for the six cancer types, (breast, colon,
liver, lung adenocarcinoma, squamous cell lung, prostate), are
downloaded from the GEO database [41] of the NCBI. For each
cancer type, we have applied the following criteria in selecting the
dataset used for this study: (1) all the data in each dataset were
generated using the same platform by the same research group; (2)
each dataset consists of only paired samples, i.e., cancer tissue
sample and the matching adjacent noncancerous tissue sample;
and (3) each dataset has at least 10 pairs of samples. In the GEO
database, only six cancer types have datasets satisfying these
criteria. A summary of the 12 datasets, 2 sets for each cancer, is
listed in Table 1.
2. Identification of Differentially Expressed Genes in
Cancer versus Control Tissues
For each dataset used in this study, we have used the normalized
expression data from the original study. Since we used only paired
data, a sign test developed by Wilcoxon [42] for matched pairs, is
applied to identify the significant differentially expressed genes in
cancer versus adjacent normal samples for each dataset. We
consider a gene being differentially expressed if the statistical
significance, p-value, is less than 0.01. For each cancer type, we
consider only genes with consistent up- or down-regulation across
all samples as differentially expressed genes. The final fold change
is calculated by taking the mean of the fold change between the
cancer and control samples.
3. Searching for Regulatory Relationships in Human
To retrieve the transcriptional regulation relationship informa-
tion about the genes we are interested in this study, we have used a
public database along with its search engine Cscan (http://www.
beaconlab.it/cscan) to predict the common transcription regula-
tors based on a large collection of ChIP-Seq data for several TFs
and other factors related to transcription regulation for human and
mouse [38]. The regulatory relationships were inferred based on
ChIP-Seq data collected under 777 different conditions in the
hmChip database [43] and transcription factors from the UCSC
Genome Browser [40].
4. Cancer Related Genes
To retrieve cancer related genes, specifically proto-oncogene
and tumor suppressor genes for our study, we searched the
UNIPROT database (http://www.uniprot.org/keywords/) using
keywords, which led to the retrieval of 232 proto-oncogenes (KW-
0656) and 194 tumor-suppressor genes (KW-0043) in human.
Supporting Information
Figure S1 Deacidification mechanisms in cancer cells. Each
rectangle bar represents a transporter, enzyme or pump family.
The red colored rectangles are up-regulated in our study and the
green show down-regulation. Dashed arrows indicate CO2
diffusion across the membrane.
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